Medicilon provides fully integrated drug-discovery and preclinical R&D services, supporting programmes from early discovery through CMC and IND-enabling studies. With 588 IND projects approved by global regulatory authorities, we deliver a proven pathway from concept to clinic. Our capabilities span medicinal chemistry, AI-driven design, ADME/DMPK, pharmacology and toxicology, complemented by specialised expertise in PROTACs, ADCs, nucleic acid therapeutics and New Approach Methodologies (NAMs). By combining advanced in vitro models with in silico AI-enabled PBPK, QSP and QST modelling, our NAMs platform provides human-relevant insights, reduces animal use and de-risks development. Through continuous innovation, we accelerate high-quality, efficient drug discovery for partners worldwide.

Contact details: Nadine Su/Marshal Ma - Medicilon UK Office, Allia Future Business Centre, Kings Hedges Road, Cambridge, CB4 2HY

T: +44 1223 981 791

M: +44 7790 816 954/+44 7723607137

E: [email protected] / [email protected]

• Member discount – Shanghai Medicilon Inc. offers fully integrated preclinical CRO services, including Chemistry, Biology, ADME, DMPK, Toxicology, and Bioanalysis. We provide One Nucleus members with an exclusive discount of 10–15%, depending on the specific project requirements